Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan

被引：29
作者：
Amarasinghe, K. [1 ]
Dalley, C.
Dokal, I.
Laurie, A.
Gupta, V.
Marsh, J.
机构：
[1] Univ London St Georges Hosp, Dept Haematol, London, England
[2] Barts & London Hosp, Acad Dept Paediat, Inst Cell & Mol Sci, London, England
[3] Dept Haematol, Ashford, Kent, England
[4] St Georges Univ London, Dept Cellular & Mol Med, London, England
来源：
BONE MARROW TRANSPLANTATION | 2007年 / 40卷 / 09期
关键词：
D O I：
10.1038/sj.bmt.1705839
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：913 / 914
页数：2
相关论文
共 9 条
[1]   Fatal diffuse capillaritis after hematopoietic stem-cell transplantation for dyskeratosis congenita despite low-intensity conditioning regimen [J].
Brazzola, P ;
Duval, M ;
Fournet, JC ;
Gauvin, F ;
Dalle, JH ;
Champagne, J ;
Champagne, MA .
BONE MARROW TRANSPLANTATION, 2005, 36 (12) :1103-1105
[2]   Dyskeratosis congenita in all its forms [J].
Dokal, I .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 110 (04) :768-779
[3]   Low-intensity hematopoietic stem-cell transplantation across human leucocyte antigen barriers in dyskeratosis congenita [J].
Dror, Y ;
Freedman, MH ;
Leaker, M ;
Verbeek, J ;
Armstrong, CA ;
Saunders, FE ;
Doyle, JJ .
BONE MARROW TRANSPLANTATION, 2003, 31 (10) :847-850
[4]   Nonmyeloablative allogeneic hematopoietic stem cell transplantation for treatment of Dyskeratosis congenita [J].
Güngör, T ;
Corbacioglu, S ;
Storb, R ;
Seger, RA .
BONE MARROW TRANSPLANTATION, 2003, 31 (05) :407-410
[5]  
Kottaridis PD, 2000, BLOOD, V96, P2419
[6]   Functional characterization of novel telomerase RNA (TEM) mutations in patients with diverse clinical and pathological presentations [J].
Marrone, Anna ;
Sokhal, Priya ;
Walne, Amanda ;
Beswick, Richard ;
Kirwan, Michael ;
Killick, Sally ;
Williams, Mike ;
Marsh, Judith ;
Vulliamy, Tom ;
Dokal, Inderjeet .
HAEMATOLOGICA, 2007, 92 (08) :1013-1020
[7]   Successful umbilical cord blood transplantation in a child with dyskeratosis congenita after a fludarabine-based reduced-intensity conditioning regimen [J].
Nobili, B ;
Rossi, G ;
De Stefano, P ;
Zecca, M ;
Giorgiani, G ;
Perrotta, S ;
Canazzio, A ;
Locatelli, F .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 119 (02) :573-574
[8]   Fludarabine, cyclophosphamide, and antithymocyte globulin for a patient with dyskeratosis congenita and severe bone marrow failure [J].
Ostronoff, Fabiana ;
Ostronoff, Mauricio ;
Calixto, Rodolfo ;
Florencio, Rodrigo ;
Domingues, Mariana C. ;
Souto Maior, Ana Patricia ;
Sucupira, Alexandre ;
Tagliari, Clemente .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (03) :366-368
[9]   Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation [J].
Vulliamy, TJ ;
Marrone, A ;
Knight, SW ;
Walne, A ;
Mason, PJ ;
Dokal, I .
BLOOD, 2006, 107 (07) :2680-2685
1